RT Journal Article
SR Electronic
T1 Annual risk of hepatitis E virus infection and seroreversion: insights from a serological cohort in Sitakunda, Bangladesh
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.28.23297541
DO 10.1101/2023.10.28.23297541
A1 Dighe, Amy
A1 Khan, Ashraful Islam
A1 Bhuiyan, Taufiqur Rahman
A1 Islam, Md Taufiqul
A1 Khan, Zahid Hasan
A1 Khan, Ishtiakul Islam
A1 Hulse, Juan Dent
A1 Ahmed, Shakeel
A1 Rashid, Mamunur
A1 Hossain, Md Zakir
A1 Rashid, Rumana
A1 Hegde, Sonia
A1 Gurley, Emily S
A1 Qadri, Firdausi
A1 Azman, Andrew S
YR 2023
UL http://medrxiv.org/content/early/2023/10/29/2023.10.28.23297541.abstract
AB Hepatitis E virus (HEV) is a major cause of acute jaundice in South Asia. Gaps in our understanding of transmission are driven by non-specific symptoms and scarcity of diagnostics, impeding rational control strategies. In this context, serological data can provide important proxy measures of infection. We enrolled a population-representative serological cohort of 2337 individuals in Sitakunda, Bangladesh. We estimated the annual risks of HEV infection and seroreversion both using serostatus changes between paired serum samples collected 9 months apart, and by fitting catalytic models to the age-stratified cross-sectional seroprevalence. At baseline, 15% (95CI: 14-17%) of people were seropositive, with seroprevalence highest in the relatively urban south. During the study, 27 individuals seroreverted (annual seroreversion risk: 15%, 95CI: 10-21%), and 38 seroconverted (annual infection risk: 3%, 95CI: 2-5%). Relying on cross-sectional seroprevalence data alone, and ignoring seroreversion, underestimated the annual infection risk fivefold (0.6%, 95CrI: 0.5-0.6%). When we accounted for the observed seroreversion in a reversible catalytic model, infection risk was more consistent with measured seroincidence. Our results quantify HEV infection risk in Sitakunda and highlight the importance of accounting for seroreversion when estimating infection incidence from cross-sectional seroprevalence data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The Bill and Melinda Gates Foundation (grant number: INV-038404).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The icddr,b research and ethics review committee and the Johns Hopkins Bloomberg School of Public Health institutional review board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data and code produced in this work are available here: https://github.com/HopkinsIDD/sitakunda-hev https://github.com/HopkinsIDD/sitakunda-hev